The sales are small in absolute and relative terms and consistent with routine portfolio management. No cause for concern unless followed by larger sales or negative fundamentals. Monitor upcoming earnings and cash flow trends.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $147.00entry
- T+1 · 9mo ago +0.68%α +1.59% · $148.00
- T+5 · 8mo ago −8.32%α −7.11% · $134.77
- T+20 · 8mo ago −35.84%α −27.91% · $94.31
- T+60 · 6mo ago −52.07%α −61.39% · $70.46
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two TransMedics insiders conducted open-market share sales within the past week, totaling approximately $299,000 in proceeds. Stephanie Lovell sold $178,500 worth of shares, and Anil Ranganath sold $120,200. David Weill exercised options but did not sell shares outright, his transaction was a derivative exercise with tax withholding likely to follow separately.
Key Financial Metrics
Key Facts
- Stephanie Lovell sold 1,193 shares at $149.62, totaling $178,497 in open-market proceeds.
- Anil P. Ranganath sold 864 shares at $139.12, totaling $120,200 in open-market proceeds.
- David Weill exercised 3,571 derivative securities at $14.20, this is not a sale but an option exercise; no open-market selling occurred in this transaction.
- Total open-market proceeds from selling insiders: $298,697.
- Total value represents ~0.006% of TransMedics' $4.8B market cap, well below materiality threshold.
Financial Impact
$298.7K in open-market share sales by two insiders; no net cash inflow to company. Derivative exercise by Weill is non-cash and does not reflect sentiment.
Risk Factors
- Perception risk if media or retail investors misinterpret derivative exercises as selling pressure.
- Potential for increased scrutiny if future sales accelerate.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (3 trades, 7d window) | cluster-TMDX-1772838805586 |
Track record
9 reports on TMDX
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +22.27% at T+60 after the Jun 11, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $90.95 Now $92.21 +1.39% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $88.24 to $91.38 Now $92.21 +4.50% ▲ +3.56% +0.96% vs SPY
- Nov 5, 202611d ago Press Release Bullish 6/10 No price data
- Jun 12, 202622w ago Institutional Cluster Bullish 6/10 Entry $72.91 to $78.79 Now $92.21 +26.47% ▲ +8.06% +7.39% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bullish 5/10 Entry $73.59 to $73.22 Now $92.21 +25.30% ▼ −0.50% −0.94% vs SPY
- Apr 10, 202631w ago DEFA14A Neutral 3/10 Entry $114.00 to $115.87 Now $92.21 −19.11% ▲ +1.64% −2.86% vs SPY
- Mar 2, 202637w ago Insider Cluster Neutral 3/10 Viewing Entry $147.00 to $134.77 Now $92.21 −37.27% ▼ −8.32% −7.11% vs SPY
- Feb 27, 202637w ago 8-K Neutral 4/10 Entry $145.26 to $129.61 Now $92.21 −36.52% ▼ −10.77% −8.79% vs SPY
- Feb 24, 202637w ago 8-K Bullish 8/10 Entry $131.85 to $147.66 Now $92.21 −30.06% ▲ +11.99% +13.09% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers